Scienta Lab
Scienta Lab develops EVA, a proprietary multimodal foundation model dedicated to Immunology & Inflammation. As part of its first use case, EVA leverages pre-clinical data of new therapeutic assets to provide early-stage evidences of human clinical efficacy. By significantly improving the clinical trial success rates of innovative, best-in-class treatments, Scienta Lab's innovation is paving the way for AI-powered precision immunology. In 2023, Scienta Lab raised 4M€ from VCs and international business angels to develop a first version of its model. Scienta Lab’s AI strategy is centered around multimodal modelling of complex biological systems, and mechanistic explainability of the deep learning models developed, to turn their unsupervised learnings into unravel new scientific discoveries.